Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

NCT06932744 ·Status: RECRUITING ·Phase: PHASE3

Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN)

NCT06454110 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.

NCT02187900 ·Status: UNKNOWN ·Phase: PHASE3

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

NCT05862233 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

NCT02052219 ·Status: WITHDRAWN ·Phase: PHASE3

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

NCT02605525 ·Status: WITHDRAWN ·Phase: PHASE2

Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

NCT00885547 ·Status: TERMINATED ·Phase: NA

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

NCT04291781 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449 ·Status: RECRUITING ·Phase: PHASE3

Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease

NCT05728684 ·Status: UNKNOWN ·Phase: NA

Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)

NCT01560052 ·Status: COMPLETED ·Phase: NA

A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

NCT05398653 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

PS-002 for the Treatment of IgA Nephropathy in Adults

NCT07182227 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Real World Study About PMN

NCT06893328 ·Status: RECRUITING

Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients

NCT05039190 ·Status: COMPLETED ·Phase: PHASE3

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

NCT06774664 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

NCT05248659 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

NCT05332210 ·Status: COMPLETED ·Phase: PHASE3

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

NCT06740526 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)

NCT06965309 ·Status: TERMINATED ·Phase: NA

Safety and Efficacy Study of VIS649 for IgA Nephropathy

NCT04287985 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

NCT05523167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

NCT05662241 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Prospective Cohort Study of Myasthenia Gravis in China

NCT06006832 ·Status: RECRUITING

To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom

NCT03368274 ·Status: UNKNOWN ·Phase: PHASE4